Prelude Therapeutics Inc financial statements

Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Prelude Therapeutics Inc files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue						7	12.1
Research and development	24.3	48.2	86.8	92.9	103	118	94.3
General and administrative	3.83	10.6	27	30.7	28.9	28.7	22.4
Operating expenses	28.1	58.8	114	124	132	147	117
Operating income	-28.1	-58.8	-114	-124	-132	-140	-105
Other non-operating income	0.54	1.83	2.04	8.1	10.4	12.5	5.07
Pre-tax income						-127	-99.5
Income tax						0	0
Net income	-27.6	-56.9	-112	-115	-122	-127	-99.5
EBITDA	-27.7	-58.2	-113	-122	-131	-138	-103
EPS, basic	-16.52	-4.56	-2.43	-2.44	-2.02	-1.68	-1.29
EPS, diluted	-16.52	-4.56	-2.43	-2.44	-2.02	-1.68	-1.29
Shares, basic (weighted)	1.67	12.5	46	47.4	60.4	75.8	77
Shares, diluted (weighted)	1.67	12.5	46	47.4	60.4	75.8	77

Balance sheet

	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	18.9	218	31.8	30.6	25.3	12.5	35.3
Short-term investments			259	171	208	121	68
Other current assets	1.35	2.5	3.88	2.65	2.65	2.28	2.48
Total current assets	20.2	221	295	204	236	136	106
Property, plant and equipment	1.65	2.48	3.93	4.91	7.33	6.77	5.11
Lease right-of-use assets			1.71	1.79	30.4	28.7	27.2
Total assets	21.9	224	305	221	278	176	141
Accounts payable	1.97	3.92	7.84	6.78	4.58	7.73	3.98
Accrued liabilities	2.6	7.46	9.62	13.1	15.8	15.2	12.5
Deferred revenue						0	33.7
Total current liabilities	4.84	11.4	19.2	21.7	21.8	25.6	53
Lease liabilities					15.4	15.3	15
Other non-current liabilities	0.01	0.03	0	3.36	3.34	3.09	2.84
Total liabilities	4.84	11.4	19.2	25.1	40.6	44.1	72.7
Paid-in capital	1.09	320	506	532	693	715	752
Retained earnings	-50.5	-107	-219	-335	-456	-584	-683
Other comprehensive income			-0.71	-1.69	0.22	0.04	0.01
Shareholders' equity	-49.4	212	286	195	237	131	68.6
Total equity	-49.4	212	286	195	237	131	68.6
Total liabilities and equity	21.9	224	305	221	278	176	141

Cash flow statement

	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-27.6	-56.9	-112	-115	-122	-127	-99.5
Depreciation and amortization	0.38	0.54	0.92	1.32	1.17	1.77	1.71
Stock-based compensation	0.85	5.58	20.9	25.1	25.6	21.3	11.9
Change in payables	0.55	1.16	3.9	-0.35	-2.27	3.31	-3.92
Cash from operations	-25.7	-46.2	-83.5	-83.7	-107	-103	-56.3
Capital expenditures	-0.78	-0.62	-2.32	-3.02	-3.51	-0.76	-0.07
Purchases of investments			-261	-119	-222	-52.7	-101
Sales and maturities of investments				204	191	144	154
Cash from investing	-0.78	-0.62	-264	81.7	-34.6	90.2	53.5
Stock issued	0.01	0.1	161	0.39	0.05	0.06	0.02
Cash from financing	29.7	246	165	0.82	136	-0.12	24.8
Net change in cash	3.28	199	-182	-1.22	-5.31	-12.8	22
Free cash flow	-26.4	-46.8	-85.9	-86.7	-111	-104	-56.4
Income taxes paid						0	0

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.65 on November 10, 2026.

Profitability

Metric	Value	How it is calculated
Operating margin	-300.6%	Operating income / revenue.
EBITDA margin	-293.5%	EBITDA (operating income + depreciation and amortization) / revenue.
Net margin	-269.7%	Net income / revenue.
FCF margin	-148.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-148.3%	Cash from operations / revenue.
Return on equity (ROE)	-45.2%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-31.9%	Net income / average total assets.
Return on invested capital (ROIC)	-49.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	309.6%	Research and development expense / revenue.
Stock-based pay / revenue	37.0%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.0%	Capital expenditures / revenue.
D&A / revenue	7.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	73.4%	Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	-47.8%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-29.4%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-20.2%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-19.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-13.8%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-8.8%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	17.6%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	43.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	4.07x	Current assets / current liabilities.
Quick ratio	3.99x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	3.99x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	29.4%	Total liabilities / total assets.
Working capital	$116.9M	Current assets - current liabilities.
Tangible book value	$133.7M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.12x	Revenue / average total assets.
Fixed asset turnover	5.10x	Revenue / average property, plant and equipment.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.61	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$0.23	Revenue / diluted weighted shares.
FCF per share	-$0.34	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.34	Cash from operations / diluted weighted shares.
Book value per share	$1.36	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.36	Tangible book value / shares outstanding.
Cash per share	$1.54	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$291.3M	Share price x shares outstanding.
Enterprise value	$139.5M	Market cap + total debt - cash - short-term investments.
P/S	13.0x	Market cap / revenue.
P/B	2.18x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.18x	Market cap / tangible book value, when positive.
EV/Sales	6.22x	Enterprise value / revenue.
FCF yield	-11.4%	Free cash flow / market cap.
Earnings yield	-20.8%	Net income / market cap (the inverse of P/E).

What was Prelude Therapeutics Inc's revenue in fiscal 2025?

Prelude Therapeutics Inc reported revenue of $12.1M for fiscal 2025, 73.4% higher than the year before.

Was Prelude Therapeutics Inc profitable in fiscal 2025?

No. It reported a net loss of $99.5M.

How much free cash flow did Prelude Therapeutics Inc generate in fiscal 2025?

Cash from operations of $56.3M minus capital expenditures of $67.0K left free cash flow of -$56.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Prelude Therapeutics Inc